Still, the pause fueled investor worries over the company’s growth as its COVID-19 shot, Novavax’s only approved product, faces low demand after a late entry into the U.S. market. Its shares ...
However, Novavax’s history of a clean safety profile with its COVID-19 vaccine and no further regulatory notices supports confidence in its ongoing operations. Additionally, Novavax’s proactive ...
Some results have been hidden because they may be inaccessible to you